Eurofins Biomnis code

E21

Synonyms

• Down syndrome
• HT21
• Serum markers for Trisomy 21
• Serum screening for Trisomy 21 risk
• Trisomy 21 - triple test
• T21 - serum markers
• T21 MSM

Specialty

Down Syndrome screening and foetal biochemistry

Clinical significance

Assays on pregnant women, of two or three markers (free beta hCG, AFP and non-conjugated oestriol on request) between the 15th and 18th week after the last menstrual period (from 14 weeks and 0 days to 17 weeks and 6 days). The risk of Down's Syndrome and neural tube non-closure is then calculated using a suitable program according to the reagents used, on the basis of the information provided by the prescribing physician (date of birth, date of gestation preferably calculated by ultrasonographic means, weight, smoker/non-smoker) and the marker levels. If the risk of Down's Syndrome is superior or equal at 1/50, the foetal karyotype is covered by French social security . When the risk is between 1/51 and 1/1000, screening by circulating free fetal DNA (NIPT) is covered by the CPAM. (applicalble for French lab only).

Preanalytics

• 3 mL :
• Serum (do not use plasma)
•   Refrigerated

• A tube specifically for this analysis : No

Further information

If a sample is taken from a gel tube, it is necessary to send a decanted serum
Non hemolysed, non-icteric, non lipemic sample. Sample must be centrifuged as quickly as possible and international samples must be frozen within 4 hours of sampling.
Please conserve an additional sample in your serolibrary until you have received the result.
In accordance with French regulation, ALWAYS attach the prescription, a copy of the ultrasound report and a copy of the patient consent form, signed by both the patient and the physician.

Documents to download

• Specific Request form B2(INTGB)

Methodology

Fluoro-Immunoassay (time resolved)

Turnaround time

3 days